Drug recall · July 19, 2023
Tiagabine Hydrochloride Tablets recall
Why: Failed Impurities: Out of Specification (OOS) result observed during Related Substances testing
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Tiagabine Hydrochloride Tablets, 2 mg, 30-count bottle, Distributed by Sun Pharmaceutical Industries. Inc. Cranbury NJ 08512, Manufactured by: Sun Pharmaceutical Industries Limited Halol-Baroda Highway, Halol-389 350, Gujarat, India. NDC#: 62756-200-83
- Lots / codes
Lot HAC3339A, Expires 07/2023
- Quantity
- 8,880 30-count bottles
- Company
- Sun Pharmaceutical Industries Inc, Princeton, NJ
- Distribution
- Distributed nationwide in the USA.
- Initiated
- July 10, 2023 · Voluntary: Firm initiated
- Classified
- July 11, 2023
- Reported
- July 19, 2023
- Ended
- December 18, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Tiagabine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.